title: Blood Assay Predicts Response to Pembrolizumab.
abstract: Researchers found that the magnitude of reinvigoration of CD8+ T cells-the peak level of Ki67 after treatment-compared with tumor burden prior to treatment with the PD-1 inhibitor pembrolizumab correlated with clinical response in patients with advanced melanoma. If this finding is confirmed in a larger cohort of patients, the ratio of these two factors could be used to determine whether a patient should continue with pembrolizumab therapy or switch to a different treatment or combination of treatments.
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage; D060890:B7-H1 Antigen / Q000097:blood; D018414:CD8-Positive T-Lymphocytes / Q000187:drug effects / Q000473:pathology*; D006801:Humans; D019394:Ki-67 Antigen / Q000097:blood*; D008545:Melanoma / Q000097:blood / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D060890:B7-H1 Antigen; D019394:Ki-67 Antigen; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; C582435:pembrolizumab